Literature DB >> 15068236

Predicting pathway perturbations in Down syndrome.

K Gardiner1.   

Abstract

Comparative annotation of human chromosome 21 genomic sequence with homologous regions of mouse chromosomes 16, 17 and 10 has identified 170 orthologous gene pairs. Functional annotation of these genes, based on literature reports and computationally-derived predictions, shows that a broad range of cellular processes are represented. A goal of Down syndrome research is to determine which of these processes are perturbed by overexpression of chromosome 21 genes, and which may, therefore, contribute to the cognitive deficits that characterize Down syndrome. Eleven chromosome 21 genes are annotated to interact with or be affected by components of the MAP Kinase pathway and eight are involved in Ca2+/calcineurin signaling. Both pathways are critical for normal neurological function, and consequently their perturbations are proposed as candidates for phenotypic relevance. We present evidence suggesting that the MAP Kinase pathway is perturbed in the Ts65Dn mouse model of Down syndrome at 4-6 months of age. Analysis is complicated by the observation that overexpression of chromosome 21 genes in trisomy may be affected by method of detection, organism, tissue or brain region, and/or developmental age.

Entities:  

Mesh:

Year:  2003        PMID: 15068236     DOI: 10.1007/978-3-7091-6721-2_2

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  15 in total

1.  The proteins of human chromosome 21.

Authors:  Katheleen Gardiner; Alberto C S Costa
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-08-15       Impact factor: 3.908

Review 2.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

3.  Upregulation of three Drosophila homologs of human chromosome 21 genes alters synaptic function: implications for Down syndrome.

Authors:  Karen T Chang; Kyung-Tai Min
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-21       Impact factor: 11.205

4.  Gene expression changes in the MAPK pathway in both Fragile X and Down syndrome human neural progenitor cells.

Authors:  Erin L McMillan; Allison L Kamps; Samuel S Lake; Clive N Svendsen; Anita Bhattacharyya
Journal:  Am J Stem Cells       Date:  2012-06-03

5.  Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease.

Authors:  Sarah B Martin; Amy L S Dowling; Joann Lianekhammy; Ira T Lott; Eric Doran; M Paul Murphy; Tina L Beckett; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.

Authors:  Jason Lockrow; Heather Boger; Heather Bimonte-Nelson; Ann-Charlotte Granholm
Journal:  Behav Brain Res       Date:  2010-04-02       Impact factor: 3.332

7.  Maternal choline supplementation in a mouse model of Down syndrome: Effects on attention and nucleus basalis/substantia innominata neuron morphology in adult offspring.

Authors:  Brian E Powers; Christy M Kelley; Ramon Velazquez; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Neuroscience       Date:  2016-11-10       Impact factor: 3.590

8.  Editing of the serotonin 2C receptor pre-mRNA: Effects of the Morris Water Maze.

Authors:  Yunzhi Du; Melissa Stasko; Alberto C Costa; Muriel T Davisson; Katheleen J Gardiner
Journal:  Gene       Date:  2007-01-12       Impact factor: 3.688

Review 9.  On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome.

Authors:  Alberto C S Costa
Journal:  Dev Neurosci       Date:  2011-09-02       Impact factor: 2.984

10.  MNB/DYRK1A phosphorylation regulates the interactions of synaptojanin 1 with endocytic accessory proteins.

Authors:  Tatyana Adayev; Mo-Chou Chen-Hwang; Noriko Murakami; Rong Wang; Yu-Wen Hwang
Journal:  Biochem Biophys Res Commun       Date:  2006-11-07       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.